Antigen News and Research RSS Feed - Antigen News and Research

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. [More]
Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. [More]
FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has granted Fast Track Designation to TxCell’s lead product Ovasave for the treatment of moderate to severe Crohn’s disease. [More]
Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Corgenix Medical Corporation, the U.S. - based operation of ORGENTEC Diagnostika, is presenting several scientific abstracts at the 2015 American Association for Clinical Chemistry Clinical Lab Expo in Atlanta. Three abstracts involve the ReEBOV Ebola rapid diagnostic test (RDT) with a fourth abstract involving the AtherOx™ Assay for assessing heart disease risk. [More]
First malaria vaccine a step closer

First malaria vaccine a step closer

Mosquirix, the first malaria vaccine to be submitted for regulatory approval, has gained the support of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). [More]
New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT). [More]
Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. [More]
Patients' own genetically engineered immune cells show significant success against multiple myeloma

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable. [More]
Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics announces FDA clearance for QUANTA Flash assays, QUANTA Flash Beta-2GP1 Domain1

Inova Diagnostics, a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration on key QUANTA Flash assays for use with Inova Diagnostics' BIO-FLASH chemiluminescent analyzer for autoimmune testing. [More]
Study findings provide basis for potential development of new methods to control HIV infection

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium. [More]
Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Immunologists from Emory University have identified a distinct set of long-lived antibody-producing cells in the human bone marrow that function as an immune archive. [More]
Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

In recent years, researchers have hotly pursued immunotherapy, a promising form of treatment that relies on harnessing and training the body's own immune system to better fight cancer and infection. Now, results of a study led by Johns Hopkins investigators suggests that a device composed of a magnetic column paired with custom-made magnetic nanoparticles may hold a key to bringing immunotherapy into widespread and successful clinical use. [More]
New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

New study evaluates impact of U.S. Preventive Services Task Force Guidelines for PSA screening

Current U.S. Preventive Services Task Force Guidelines for prostate screening may be impacting the detection of high-risk prostate cancer. [More]
New UW-Madison study links two unrelated cancer treatments

New UW-Madison study links two unrelated cancer treatments

A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials. [More]
Microbiota blocks the immune cells responsible for triggering allergies

Microbiota blocks the immune cells responsible for triggering allergies

The human body is inhabited by billions of symbiotic bacteria, carrying a diversity that is unique to each individual. The microbiota is involved in many mechanisms, including digestion, vitamin synthesis and host defense. [More]
Turnstone announces ongoing enrollment of Marabex clinical trial

Turnstone announces ongoing enrollment of Marabex clinical trial

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours. [More]
Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics. [More]
Aytu BioScience now trading under new symbol following its corporate name change

Aytu BioScience now trading under new symbol following its corporate name change

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the company is now trading under the new symbol "AYTU," following its corporate name change, which became effective June 8, 2015. [More]
City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

City of Hope researchers to use patients' own modified T cells to treat advanced brain tumors

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine's biggest challenges: brain cancer. This month, they will launch a clinical trial using patients' own modified T cells to fight advanced brain tumors. [More]
ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies. [More]
Advertisement
Advertisement